Synapsoft logo
AI Insights from Disclosures
Searching...
AprilBio Co.,Ltd. 397030
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
AprilBio Co.,Ltd. is a research and development-focused company established in 2013 as a faculty startup, developing antibody therapeutics and long-acting recombinant protein drugs, which belong to protein drugs among biopharmaceuticals, based on human antibody production technology and technology for extending the half-life of protein drugs. The company possesses an antibody library (HuDVFab library) technology that can discover various antibodies and obtain human antibody new drug candidates with the desired target antigen-binding ability, as well as the SAFA (anti-Serum Albumin Fab-Associated technology) platform technology, a long-acting source technology that extends the serum half-life of therapeutic proteins by utilizing a human Fab antibody fragment (named SL335) selected from the company's antibody library that binds specifically and with high affinity to serum albumin.
Representative Director Cha Sanghun
Founded January 30, 2013
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 14011-0050944
Business number 221-81-42488
Phone Number 070-4027-7616
Fax Number 02-6956-8384
Company Address 1 Kangwondaehak-gil, Chuncheon-si, Gangwon-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant